FILTER

Refine your search with the following facets to narrow down your results.

7 Current news of Keryx Biopharmaceuticals

Keryx Biopharmaceuticals Initiates Phase 2 Study of Zerenex for the Treatment of Non-Dialysis Dependent Chronic Kidney Disease

07-Nov-2012 - Keryx Biopharmaceuticals, Inc. announced the initiation of a Phase 2 study of Zerenex™ (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate, in managing serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney ...

chronic renal disease iron deficiency phase II studies

Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate

25-Apr-2012 - Keryx Biopharmaceuticals, Inc. announced that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd. (Torii), has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease ...

ferric citrate hemodialysis hyperphosphatemia +1

Keryx Biopharmaceuticals Receives Positive Scientific Advice from the European Medicines Agency for Zerenex in Hyperphosphatemia

03-May-2011 - Keryx Biopharmaceuticals, Inc. announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) for the development of Zerenex™ (ferric citrate) for the management and control of serum phosphorus in end-stage renal disease (ESRD) patients undergoing dialysis, and ...

chronic renal disease

Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer

12-Apr-2010 - Æterna Zentaris Inc. announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401), the Company's potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory ...

clinical trials colorectal cancer food +2

Æterna Zentaris Announces Perifosine Receives FDA Fast Track Designation for Treatment of Refractory Advanced Colorectal Cancer

07-Apr-2010 - Æterna Zentaris Inc. announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt ...

colorectal cancer food metastatic colorectal cancer

Æterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine

18-Sep-2009 - Æterna Zentaris Inc. announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received orphan-drug designation for this compound from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. In August, ...

food multiple myeloma Orphan Drug Designation

Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint

11-Mar-2008 - Keryx Biopharmaceuticals, Inc. announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the treatment of diabetic nephropathy. The Company announced that this Phase 3 clinical trial failed to meet the primary objective of the study, which was to increase ...

clinical trials drug development inhibitors +1